Top Back to top

CLL - Projects about PI, ibrutinib and venetoclax

Chronic Malignancies Working Party (CMWP)
Study number:
 
Short title:
 
Study status:
Collecting data
Deadline for data collection:
Study design:
Retrospective study design
Primary objective:
AlloSCT after Multiple Pathway Inhibitors:
We hypothesize that many nowadays transplanted patients for CLL have been pretreated with at least two pathway inhibitors (PI). The aim of this study is to describe the outcome of alloSCT of these patients in terms of PFS, OS, cumulative incidence of relapse (CIR) and NRM.

AlloSCT after stopping Ibrutinib for intolerance or relapse:
The aim of this study is to describe the outcome of alloSCT in CLL patients that were transplanted after Ibrutinib cessation in terms of PFS, OS, CIR and NRM.

Venetoclax before and after alloSCT for CLL:
Venetoclax is currently more and more widely used for relapsed CLL. Data on the use of Venetoclax before alloSCT or after alloSCT in the event of relapse or persistence of a detectable residual disease are lacking. The aim of this study is to describe the outcome of alloSCT in CLL patients that were transplanted after venetoclax use and/or treated with venetoclax after alloSCT in terms of PFS, OS, CIR and NRM and the response rate, PFS and OS in case venetoclax was given after alloSCT .
Key inclusion criteria:
o Patients diagnosed with Chronic Lymphocytic Leukemia.
o Received Allogeneic HSCT between 2015 and 2020.
o No Richter’s transformation before first allogeneic HSCT.
o No previous autologous HSCT before first allogeneic HSCT
o Adults (≥18 years).
Country:
 
Principal investigator:
Olivier Tournilhac, Michel van Gelder
Principal investigator email:
 
EBMT Study coordinator:
Nadia Erazo Castillo
Study coordinator email:
cmwpebmt@lumc.nl